| 0.715 -0.115 (-13.85%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.05  |
1-year : | 1.22 |
| Resists | First : | 0.89 |
Second : | 1.05 |
| Pivot price | 0.67 |
|||
| Supports | First : | 0.57 |
Second : | 0.38 |
| MAs | MA(5) : | 0.75 |
MA(20) : | 0.65 |
| MA(100) : | 1.89 |
MA(250) : | 4.59 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 77.2 |
D(3) : | 84.6 |
| RSI | RSI(14): 42.5 |
|||
| 52-week | High : | 15.75 | Low : | 0.16 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MBRX ] has closed below upper band by 36.2%. Bollinger Bands are 71.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.9 - 0.9 | 0.9 - 0.91 |
| Low: | 0.7 - 0.71 | 0.71 - 0.71 |
| Close: | 0.71 - 0.72 | 0.72 - 0.72 |
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.
Fri, 11 Sep 2026
MBRX: Annamycin's Phase III AML trial shows triple the remission rate of control with zero cardiotoxicity - TradingView
Fri, 11 Sep 2026
Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand - GlobeNewswire
Fri, 11 Sep 2026
A biotech’s clinical update goes online before New York investor meetings - Stock Titan
Sat, 05 Sep 2026
Moleculin Biotech Stock Price Forecast. Should You Buy MBRX? - StockInvest.us
Sat, 05 Sep 2026
MBRX Should I Buy - Intellectia AI
Mon, 31 Aug 2026
Moleculin (NASDAQ: MBRX) posts investor presentation online - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 1.703e+007 (%) |
| Held by Institutions | 6.4 (%) |
| Shares Short | 1,050 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.883e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -84.6 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 194.57 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 14.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0.83 |
| Dividend | 0 |
| Forward Dividend | 316390 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|